Image-guided radiation therapy developer ViewRay reported a boost in first-quarter revenue (end-March 31) over the same quarter last year.
Total revenue for the first quarter was $26.2 million, up from $1.2 million for the same period last year, which the company attributed in part to four MRIdian system installations and one system upgrade. ViewRay's net loss was $7.5 million, compared with a net loss of $28 million for the first quarter last year.
Moving forward, ViewRay anticipates 2018 total revenue to be in the range of $80 million to $90 million, it said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
